PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 29, 2026Frontiers in Immunology0 citationsOpen Access

Pathological complete response following immunotherapy in dMMR/MSI-H ascending colon primary squamous cell carcinoma: a case report

CXChaoxian XiongWWWei WangXCXuefeng Cha

Key Points

  • To illustrate the effectiveness of PD-1 blockade therapy in a rare case of dMMR/MSI-H ascending colon squamous cell carcinoma.
  • Case report featuring a patient with dMMR/MSI-H SCC
  • Administered four cycles of PD-1 blockade monotherapy
  • Conducted surgical resection after treatment
  • Achieved significant tumor regression after immunotherapy
  • Pathological complete response (pCR) confirmed post-surgery
  • Indicates potential for anti-PD-1 therapy in rare SCC subtypes

Abstract

Primary colon squamous cell carcinoma (SCC) is an extremely rare malignancy and associated with a poor prognosis. This case report describes a patient with deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) ascending colon SCC, who was treated at our institution. After receiving four cycles of programmed cell death -1 (PD-1) blockade monotherapy, the tumor exhibited significant regression, and pathological complete response (pCR) was achieved following surgical resection. This case demonstrates that Anti-PD-1 therapy can induce clinically meaningful tumor regression even in this rare colon SCC subtype, suggesting a potential treatment strategy for dMMR/MSI-H colon SCC. These findings may provide valuable insights for clinicians managing similar cases. However, the feasibility and safety of immunotherapy in dMMR/MSI-H primary colon SCC require further validation through additional clinical studies.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Xiong et al. (2026) studied this question.

synapsesocial.com/papers/69c8c0b0de0f0f753b39b98bhttps://doi.org/10.3389/fimmu.2026.1688501
Ask AI
Helpful
Bookmark
Share
View Full Paper